the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma.
Official Title A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma
Principal Investigator Jakubowiak, Andrzej
Brief Summary At least one dose level of AMG 176 will achieve acceptable safety and tolerability in subjects with relapsed or refractory multiple myeloma
Gender Both
Ages 18 Years
Enrollment 85
Accepts Healthy Volunteers No
Lead Sponsor AmgenIndustry
Collaborator
Study Design Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
Study Phase Phase 1
Study Type Interventional
Contact Name
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Relapsed or Refractory Multiple Myeloma
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI